Search results
Results from the WOW.Com Content Network
In 2010, the All-Party Parliamentary Group on Involuntary Tranquilliser Addiction filed a complaint with the Equality and Human Rights Commission under the Disability Discrimination Act 1995 against the Department of Health and the Department for Work and Pensions alleging discrimination against people with a benzodiazepine prescription drug ...
Alprazolam, sold under the brand name Xanax among others, is a fast-acting, potent tranquilizer of moderate duration within the triazolobenzodiazepine group of chemicals called benzodiazepines. [15] Alprazolam is most commonly prescribed in the management of anxiety disorders , especially panic disorder and generalized anxiety disorder (GAD). [ 9 ]
In Northern Ireland statistics of individuals attending drug addiction treatment centers found that benzodiazepines were the 2nd most commonly reported main problem drugs (31 percent of attendees). Cannabis was the top with 35 percent of individuals reporting it as their main problem drug.
In some cases, it can begin to look like addiction.” Many people don’t understand how powerful Xanax is. Phoebe, who had a family history of drug addiction, was hesitant to take the medication ...
There’s a high risk of dependency and addiction. There’s a reason why alprazolam is typically prescribed for short-term use — because when used for a longer period of time, it can ...
A physical dependence develops more quickly with higher potency benzodiazepines such as alprazolam (Xanax) than with lower potency benzodiazepines such as chlordiazepoxide (Librium). [10] Symptom severity is worse with the use of high doses, or with benzodiazepines of high potency or short half-life.
Benzodiazepine overdose (BZD OD) describes the ingestion of one of the drugs in the benzodiazepine class in quantities greater than are recommended or generally practiced. . The most common symptoms of overdose include central nervous system (CNS) depression, impaired balance, ataxia, and slurred spee
A 2012 study conducted by the National Center on Addiction and Substance Abuse at Columbia University concluded that the U.S. treatment system is in need of a “significant overhaul” and questioned whether the country’s “low levels of care that addiction patients usually do receive constitutes a form of medical malpractice.”